Zentiva Overview
- Founded
- 1993
- Status
- Public
- Employees
- 4,700
- Stock Symbol
- 1SKF401E
- Investments
- 6
- Share Price
- $39.78
- (As of Wednesday Closing)
Zentiva General Information
Description
Zentiva AS is engaged in the development, production, and distribution of generic medicines. It operates in more than 25 European markets. The company therapeutic areas inlcude Cardiovascular, Central nervous system, Gastrointestinal and metabolic disorders, Anti-inflammatory and pain, Ophthalmology, Anti-infectives, Urology, Respiratory, Blood disorders, and Oncology.
Contact Information
Website
www.zentiva.com
Formerly Known As
Leciva
Ownership Status
Publicly Held
Financing Status
Private Equity-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
XBRA
Primary Office
- U kabelovny 529/16
- Dolní Měcholupy
- Prague, 102 00
- Czech Republic
+420 267 000 000
Zentiva Timeline
Zentiva Stock Performance
(As of Wednesday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $39.78 | $34.51 | $12.93 - $112.05 | 3.17 |
Zentiva Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2015 | FY 2015 31-Dec-2015 | FY 2014 31-Dec-2014 |
|---|---|---|---|
| Revenue | 125,622 | 125,622 | 185,331 |
| EBITDA | 37,918 | 37,918 | 67,796 |
| Net Income | 19,452 | 19,452 | 53,052 |
| Total Assets | 149,351 | 149,351 | 191,232 |
| Total Debt | 0 | 0 | 23 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Zentiva Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
This information is available in the PitchBook Platform. To explore Zentiva‘s full profile, request access.
Request a free trialZentiva Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Zentiva AS is engaged in the development, production, and distribution of generic medicines. It operates in more than 25
Drug Discovery
Prague, Czech Republic
4,700
As of 2022
00000
00
0000-00-00
000000&0
0000000
t dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut al
0000 000000000
Cambridge, MA
0000
As of 0000
00.000
000000000
00.000
000000 0
etur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad
000000000000000
Foster City, CA
00000
As of 0000
00.000
000000000
00.000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialZentiva Competitors (43)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | 0000 | 00.000 | 000000000 | 00.000 |
| 000000 00000000 | Formerly VC-backed | Foster City, CA | 00000 | 00.000 | 000000000 | 00.000 |
| 00000000 000000000 | Corporation | Henderson, NV | 000 | 00000 | 000000 - 000 | 00000 |
| 000000000 00000000 | Corporation | Pasadena, CA | 000 | 00.000 | 000000 - 000 | 00.000 |
| 00000000 000000000 | Corporation | Gaithersburg, MD | 0000 | 00000 | 000000000 | 00000 |
Zentiva Patents
Zentiva Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| GB-2592680-A8 | Pharmaceutical compositions comprising dasatinib anhydrous and uses thereof | Pending | 06-Mar-2020 | 0000000000 | |
| GB-2592680-A | Pharmaceutical compositions comprising dasatinib anhydrous and uses thereof | Pending | 06-Mar-2020 | 0000000000 | 0 |
| EP-3811932-A1 | Dosage form of apalutamide | Pending | 22-Oct-2019 | 0000000000 | 0 |
| EP-3766484-B1 | Solid pharmaceutical dosage form comprising valsartan and sacubitril | Active | 19-Jul-2019 | 0000000000 | |
| EP-3766484-A1 | Solid pharmaceutical dosage form comprising valsartan and sacubitril | Granted | 19-Jul-2019 | A61K9/1617 | 0 |
Zentiva Executive Team (7)
| Name | Title | Board Seat | Contact Info |
|---|---|---|---|
| Nick Haggar | Chief Executive Officer | ||
| Kenneth Lynard | Chief Financial Officer |
Zentiva Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialZentiva Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
This information is available in the PitchBook Platform. To explore Zentiva‘s full profile, request access.
Request a free trialZentiva Investments & Acquisitions (6)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 0000000000000 | 29-May-2020 | 0000000000 | 000.00 | Buildings and Property | 0000 0000 |
| 00000000 0000 | 07-Apr-2020 | 0000000000 | Pharmaceuticals | 0000 0000 | |
| 00000000 0000 | 31-May-2019 | 0000000000 | Pharmaceuticals | 0000 0000 | |
| 0000 000000 | 01-Apr-2019 | 0000000000 | Distributors/Wholesale | 0000 0000 | |
| Sicomed | 12-Oct-2005 | Merger/Acquisition | 00000 | Pharmaceuticals |
Zentiva Subsidiaries (2)
| Company Name | Industry | Location | Founded |
|---|---|---|---|
| Labormed Alvogen | Pharmaceuticals | Bucharest, Romania | 1991 |
| 00000000 000000 | Pharmaceuticals | Bucharest, Romania |
Zentiva Exits (1)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 000000 00000000000 | 11-Aug-2003 | 0000000000 | Completed |
|